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Key Points
Bone marrow progenitors, monocytes, and myeloid DCs contain BRAF  alleles in adults with
LCH and ECD.
Mutant allele distribution is not disease specific, but precursors have distinct LCH-like and
macrophage differentiation capacities.
Abstract
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are rare histiocytic disorders
induced by somatic mutation of MAPK pathway genes. BRAF  mutation is the most common
mutation in both conditions and also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL). It is
not known if adult LCH or ECD arises from hematopoietic stem cells (HSCs), nor which potential blood
borne precursors lead to the formation of histiocytic lesions. In this study, BRAF  allele–specific
polymerase chain reaction was used to map the neoplastic clone in 20 adults with LCH, ECD, and HCL.
BRAF  was tracked to classical monocytes, nonclassical monocytes, and CD1c  myeloid dendritic
cells (DCs) in the blood, and mutations were observed in HSCs and myeloid progenitors in the bone
marrow of 4 patients. The pattern of involvement of peripheral blood myeloid cells was indistinguishable
between LCH and ECD, although the histiocytic disorders were distinct to HCL. As reported in children,
detection of BRAF  in peripheral blood of adults was a marker of active multisystem LCH. The
healthy counterparts of myeloid cells affected by BRAF mutation had a range of differentiation potentials
depending on exogenous signals. CD1c  DCs acquired high langerin and CD1a with granulocyte-
macrophage colony-stimulating factor and transforming growth factor β alone, whereas CD14  classical
monocytes required additional notch ligation. Both classical and nonclassical monocytes, but not CD1c
DCs, made foamy macrophages easily in vitro with macrophage colony-stimulating factor and human
serum. These studies are consistent with a hematopoietic origin and >1 immediate cellular precursor in both
LCH and ECD.
Introduction
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Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are rare inflammatory myeloid
neoplasms principally caused by mutations in the MEK–extracellular signal-regulated kinase (ERK)
signaling pathway, most commonly involving BRAF.  LCH has a peak of incidence in childhood, but an
increasing number of adults are now also diagnosed, including some with a poor outcome because of
multisystem LCH (MS-LCH).  ECD, once considered a form of “non-Langerhans” histiocytosis, appears
to be a related condition by virtue of a common genetic landscape and the histological evidence of
coexistent LCH and ECD in a proportion of adult patients.  In contrast with LCH, ECD is rarely seen in
children and predominantly affects older males.
In children with MS-LCH caused by BRAF  allele–specific polymerase chain reaction (PCR) has been
used to demonstrate mutant alleles in CD14  and CD11c  peripheral blood populations.  A hematopoietic
origin was corroborated in 2 cases of MS-LCH through expansion of hematopoietic clones in vitro.  These
studies support a model in which MS-LCH arises in the hematopoietic stem cells (HSCs) and is
disseminated to the periphery by myeloid cells carrying somatic mutation.  However, the identity of
blood-borne cells that give rise to peripheral tissue histiocytes remains open to further investigation,
because >1 cell type carries BRAF  and myeloid lineages may have overlapping differentiation
potentials.
Human peripheral blood contains several subsets of myeloid mononuclear cells. Monocytes comprise
∼10% of mononuclear cells and may be divided into classical, nonclassical, and intermediate on the basis
of CD14 and CD16 expression.  All human monocytes express CD11c. CD14  classical monocytes are
the most numerous and can be differentiated into macrophages and dendritic cells (DCs) in vitro. Blood
DCs comprise 1% to 2% of mononuclear cells and are subdivided into CD123  plasmacytoid DCs and 2
subsets of CD11c  myeloid DCs expressing CD1c  and CD141 .  CD1c  DCs are the major population
of myeloid DCs in blood and tissues. They may express langerin in vivo  and readily acquire a
Langerhans cell–like phenotype in vitro.
The differentiation potentials of monocytes and blood DCs overlap, and monocyte-derived DCs bear many
markers in common with CD1c  myeloid DCs.  Monocytes have plasticity in many directions including
DC and macrophage axes  and may also express langerin in vitro under certain conditions.  Thus
multiple blood-derived populations have the potential to contribute to histiocytic lesions.
The precursor populations of adults with LCH, ECD, or LCH/ECD crossover disease remain undefined. It
is not known whether MS-LCH in adults correlates with the presence of mutant alleles in peripheral blood
or if it is possible to discern a similar risk stratification in patients with ECD. NRAS mutation was detected
in the CD14  fraction of peripheral blood mononuclear cells (PBMCs) in 1 patient,  and ERK activation
was reported in 1% to 3% of monocytes of an ECD cohort.  However, the involvement of other myeloid
lineages has not been evaluated in ECD.
Recent RNA sequencing suggests that LCH lesions are enriched for DC gene transcripts, whereas biopsies
of ECD are enriched for myeloid precursor and macrophage gene expression.  It has been suggested that
DC pathways of development may be involved in the generation of LCH, whereas monocyte-macrophage
differentiation could give rise to ECD. Finally, BRAF  has been detected in HSCs of patients with
hairy cell leukemia (HCL) and confirmed by xenografting.  There does not appear to be a clinical overlap
between HCL and histiocytosis, and the pathogenesis of these 2 different conditions from a common
somatic mutation is poorly understood. HCL is therefore an interesting disease to evaluate in parallel and
provides a useful control for the specificity of allele mapping in histiocytosis.
In this report, we have analyzed the distribution of BRAF  in the peripheral blood and bone marrow
(BM) progenitor compartments of adults with MS-LCH, LCH/ECD crossover, and ECD. We sought to
determine whether mutant alleles could be tracked to the HSCs and whether there was a correlation
between the architecture of the neoplastic clone and the clinical phenotype of histiocytosis. We also aimed
to intersect these observations with studies to determine the potential of DC and monocyte lineages to
generate LCH-like cells and foamy macrophages as in vitro surrogates of pathological histiocytes.
Methods
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Patient samples, lesional BRAF  testing, and clinical data
Blood, skin, BM, and surplus biopsy material were obtained from LCH and ECD patients referred to a local
clinic with ethical approval from the Newcastle and North Tyneside Research Ethics Committee. Genomic
DNA from formalin-fixed paraffin-embedded LCH lesions was extracted using Promega Maxwell Tissue
DNA Purification Kits (Promega; http://www.promega.co.uk), and the region flanking codon 600 amplified
by PCR. Amplicons were purified and genotyped by primer extension for the c.1799T>A, p.Val600Glu
(V600E) using the Sequenom iPlex protocol (Sequenom; http://www.sequenom.com). The extension
products were detected by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass
spectrometry using a Sequenom Typer 4.0. Disease activity was assessed by radiological examination
including magnetic resonance imaging and positron emission tomography.
Flow cytometry
Absolute quantitation was performed using TruCount tubes on whole blood with a single-step lyse no-wash
protocol. For more detailed analysis, whole blood was separated by density centrifugation into
mononuclear and red cell/neutrophil fractions. The red cell pellet was subsequently used for extraction of
neutrophil DNA. Flow cytometry was performed on an LSRII or LSR Fortessa X20 cytometer from Becton
Dickinson (BD; http://www.bd.com), and data were analyzed with FlowJo (Treestar). Fluorescence-
activated cell sorting was performed using a BD FACS Aria. Sorted cells were collected into microfuge
tubes containing RPMI with 10% fetal calf serum.
Antibodies were from BD unless stated otherwise and are denoted as follows: antigen fluorochrome (clone)
CD1a BV421 (HI149; Biolegend; http://www.biolegend.com); CD1c APC (AD5-8E7; Miltenyi Biotec;
http://www.miltenyibiotec.com); CD3 FITC (SK7); CD3 V500 (UCHT1); CD7 FITC (4H9); CD10 PE-TR
(B-Ly6; Beckman Coulter; http://www.beckmancoulter.com); CD11c A700 (B-ly6); CD14 APCCy7
(MΦP9); CD14 FITC (M5E2); CD16 FITC (NKP15/Leu-11a); CD16 PeCy7 (B73.1); CD19 FITC (4G7);
CD19 PECy7 (SJ25C1); CD20 FITC (L27); CD34 PE (8G12); CD34 FITC (8G12); CD34 APC (581);
CD38 PECy7 (HB7); CD45 V450 (2D1); CD45 APCCy7 (2D1); CD45RA BV510 (HI100; Biolegend);
CD56 FITC (NCAM16.2); CD90 PerCPCY5.5 (5E10; Biolegend); CD123 PerCPCY5.5 (7G3); CD123 PE
(9F5); CD207 PE (DCGM4; Beckman Coulter); HLA-DR V500 (L243/G46-6); and HLA-DR A700
(L243/G46-6).
BRAF  allele–specific PCR
Genomic DNA from sorted blood cells, BM cells, control cell lines, or cell-free sources was extracted using
Qiagen micro-kits (Qiagen; http://www.qiagen.com). BRAF mutation and reference quantitative PCR was
performed with competitive allele-specific Taqman mutation detection assays: Mutation Allele Assay,
BRAF_476_mu 4465804 Hs00000111_mu; Gene Reference Assay, BRAF_rf - 4465807 Hs00000172_rf,
according to the manufacturer’s instructions (Life Technologies; http://www.lifetechnologies.com). A
standard curve was derived from 6 serial dilutions of genomic DNA from BRAF  melanoma cell line
A375 and Epstein-Barr virus–transformed lymphoblastoid cell lines; 0%, 0.1%, and 10% V600E mutation
controls were performed with every run. The percentage of BRAF  mutation was determined from the
dCT (CT reference − CT mutant) using the standard curve. Graphs were plotted with Prism Version 5.0
(GraphPad Software Inc.).
In vitro differentiation
Aliquots of 10 000 sorted cells from healthy controls were cultured in RPMI 1640 with 10% fetal bovine
serum or 5% human serum in 100 µL in 96-well plates. Supplements were added: granulocyte-macrophage
colony-stimulating factor (GM-CSF), 50 ng/µL; transforming growth factor β (TGF-β), 10 ng/µL;
macrophage colony-stimulating factor (M-CSF), 50 ng/µL. Cultures were maintained for 3 days before
analysis by flow cytometry. For phase-contrast microscopy, cells were cultured in Thermo Scientific Nunc
chamber slides system for 7 days, washed gently, and fixed with 1% paraformaldehyde in phosphate-
buffered saline, and images were acquired with Carl Zeiss Axioplan 2 ×40 objective and Carl Zeiss
Axiovision software release 4.8.
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Statistical methods
Mann-Whitney U tests, Student t tests, and Fisher’s exact test were performed using GraphPad Prism 5.0
software.
Results
Fifty-two adults with histiocytosis and 4 with HCL were recruited from a local clinic and collaborating
centers (Figure 1). Twenty with histiocytosis and all with HCL had confirmed BRAF  lesions. Three
additional children with BRAF -mutated LCH were included in some analyses for comparison. Further
clinical details are given in supplemental Table 1 (available on the Blood Web site).
Detection of BRAF  was performed using an allele-specific PCR and was sensitive to 0.01% with a
quantitative range to 0.1% (Figure 2A). BRAF  alleles were detectable in DNA isolated from PBMCs
of patients with active MS-LCH with or without coexistent ECD (LCH/ECD crossover) but were only
present in 1 patient with single-system (SS) LCH (Figure 2B). ECD is not conventionally classified into SS
or MS. Nearly all cases involved multiple systems. There was no clear correlation between clinical features
and BRAF  detection in the PBMCs (see supplemental Table 1 for details).
A simple linear correlation was observed between the frequency of mutant allele detection in PBMCs vs
cell-free plasma DNA, with approximately half-log greater sensitivity for detection in cellular DNA (
Figure 2C). In order to exclude the uptake of free DNA into the cell-associated pool by phagocytosis or
macropinocytosis, purified BRAF -mutated DNA from A375 cells was incubated with whole blood of
healthy controls (Figure 2Di), and sorted cell fractions were cultured with medium containing 20% serum
from a patient with HCL (Figure 2Dii). Cellular and cell-free DNA was then recovered and subjected to
PCR. Mutated BRAF alleles were only recovered from the cell-free fraction, but not the cellular DNA,
indicating that uptake of exogenous DNA did not account for cell-associated BRAF . With patient
serum, cell cultures not only remained negative but diluted or degraded the cell-free signal.
The pattern of mononuclear cells observed by flow was analyzable by conventional gating, and no atypical
populations were detected (supplemental Figure 1). Neither langerin CD1a  LCH-like cells nor
CD103 CD11c  hairy cells were detectable in the peripheral blood of any of the histiocytosis patients
(supplemental Figure 1). Absolute counting of PBMCs from patients with histiocytosis revealed
monocytosis and increased numbers of total CD11c  and CD11c CD1c  myeloid cells (supplemental
Figures 1 and 2). There were no detectable differences between BRAF-mutated and WT disease, although
power to detect subgroup differences was limited. No cytological atypia was observed among monocytes
and DC subsets (supplemental Figure 3).
In order to map the distribution of mutant alleles, PBMCs from 9/11 patients with circulating BRAF
and 2 children with MS-LCH were fractionated into 4 quadrants according to the expression of HLA-DR
and lineage (CD3, CD19, CD20, and CD56). The gates were completely apposed in order to account for all
mutant alleles present in PBMCs and to exclude the inadvertent loss of signal to an uncharacterized
disease-related population.
In contrast to patients with HCL, in which BRAF  was largely confined to the HLA-DR lineage
quadrant containing hairy cells, mutation in patients with histiocytosis was highly enriched in the HLA-
DR lineage  quadrant containing monocytes and DCs (Figure 3A). Some overspill into adjacent quadrants
was observed, owing to the close gating. For example, in histiocytosis patients, positivity appeared in the
HLA-DR lineage  quadrant. This was further studied in case A2951 and found to be associated with
CD14  monocytes and CD11c  myeloid precursors expressing low HLA-DR at the top of the double-
negative gate (data not shown).
The mononuclear compartment was further fractionated to explore the distribution of mutant alleles at
higher resolution (supplemental Figures 1 and 2; Figure 3B). As expected, BRAF  was localized to
hairy cells with a low level of alleles detectable in phenotypically normal B and NK cells but none in the
remaining monocytes and myeloid cells. In contrast, the majority of alleles in patients with histiocytosis
were found in CD14  classical monocytes, CD16  nonclassical monocytes, and CD11c CD1c  myeloid
DCs. Plasmacytoid DCs harbored some alleles in LCH patients, and in 1 case, BRAF  was also
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detectable at a low level in B and T cells. The distribution of alleles did not vary significantly between
LCH, ECD, and patients with LCH/ECD. In addition to these compartments, we studied CD14 CD16
intermediate monocytes and CD11c CD1c  myeloid cells in a subset of patients (see supplemental Figures
1, 2, and 4 for details). These did not differ significantly from the allele level in CD14  classical monocytes
and CD1c  myeloid DCs, respectively.
BRAF  mutation was previously reported in children with MS-LCH, using a more simple gating
strategy to obtain CD14  and CD11c  myeloid cells.  CD11c  myeloid cells comprise multiple fractions
including CD1c  myeloid DCs, CD16  nonclassical monocytes, and CD11c CD1c  cells, which were
analyzed separately here. The relationship between these populations is summarized in supplemental Figure
4.
In order to probe the hematopoietic origin of LCH and ECD, BM was analyzed from 2 patients with MS-
LCH and 2 with ECD. One ECD patient (A7344) had mutated NRAS rather than BRAF and was previously
reported to have a high level of NRAS mutation in CD14  peripheral blood monocytes (A7344).  A
commonly used schema for immunophenotyping (supplemental Figure 5) revealed that the common
myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) compartments were relatively
expanded (Figure 4A). BRAF  was detectable in CD90 CD45RA CD38  HSCs,
CD38 CD45RA  CMP, and CD45RA  GMP (Figure 4B). The mutant allele was present at <1% in
HSCs and was most enriched in the CMP fraction. Mature histiocytes arising from the mutated clone were
rigorously excluded in this analysis (supplemental Figure 5). A pediatric patient included for comparison
showed a similar distribution of alleles. The NRAS-mutated patient was quantified by peak height on
Sanger sequencing at 21% to 63% in myeloid precursor fractions. Progenitor cells from this patient were
demonstrated to engraft in immunodeficient mice, in the accompanying paper.
These results suggest that LCH and ECD arise in the HSCs and are transmitted to peripheral tissues by
blood-borne myeloid cells. However, there was no obvious disease-specific bias in the distribution of
mutant alleles among myeloid cells that might correlate phenotypic differences between LCH and ECD. We
therefore evaluated the potential of each myeloid fraction to give rise to the characteristic cells of LCH and
ECD lesions through in vitro differentiation of sorted fractions from healthy controls.
It has previously been demonstrated that monocytes and CD1c  DCs can express langerin in vitro under
different conditions, but only cells with high langerin and CD1a contain Birbeck granules.
Previous reports are discordant and have not examined monocytes and DCs from peripheral blood and
compared their differentiation capacity in the same platform. We therefore tested the development of a
Langerhans cell (LC)–like phenotype by blood monocytes and CD1c  DCs using conditions that had been
previously described in either monocytes or DCs : soluble factors GM-CSF and TGF-β and the
notch ligands δ-like protein 1 (DLL1) and DLL4, expressed on mouse OP9 cells. In order to study the
potential to develop foamy macrophage morphology, we used M-CSF with 5% human serum.
As shown previously, CD1c  DCs attained high langerin expression with GM-CSF and TGF-β alone.
Soluble factors GM-CSF and TGF-β were not sufficient to induce high langerin in CD14  monocytes, but
this potential was revealed by coculture with notch ligands DLL1 and DLL4. CD16  monocytes did not
express high langerin under any conditions, but notch ligation also further enhanced the expression of
langerin by CD1c  DCs in response to soluble factors (Figure 5; supplemental Figure 6). In macrophage
differentiation conditions, CD1c  DCs were unable to form foam cells, whereas both monocyte subsets
developed this phenotype. A summary of the distribution of BRAF alleles and differentiation potential of
myeloid lineage affected is shown in Table 1.
Discussion
Prior to the discovery of BRAF , there was accumulating evidence that both LCH and ECD were
clonal proliferations of histiocytes, including a remarkable insight by Chetritt et al that ECD was the
“macrophage counterpart to LCH.”  Here we have exploited the recurrent BRAF  mutation to map
the neoplastic clones of LCH and ECD. The results further reinforce the concept that LCH and ECD are
closely related hematopoietic neoplasms, regardless of their distinctive pathological features.
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A high-resolution analysis of myeloid cells demonstrated the highest frequency of mutant alleles in CD14
classical monocytes, CD16  nonclassical monocytes, and CD1c  myeloid DCs. Unexpectedly, the
nonclassical monocyte is a reservoir of BRAF mutation and accounts for a proportion of the signal
previously tracked to CD11c  myeloid cells.  We also mapped BRAF mutation to cells defined by
phenotype as HSCs in LCH, ECD, and HCL. BRAF  has previously been reported in HSCs of children
with MS-LCH  and patients with HCL,  and it remains unclear how the same mutation present in HSCs
generates such unrelated pathologies. Although there is a documented overlap between LCH and ECD,
HCL is unrelated in incidence, and we did not observe HCL leukocytes in any patient with histiocytosis.
The initial cell-sorting approach adopted apposed gating of the HLA-DR vs lineage plot of total PBMCs in
order to account for all the mutated alleles present in PBMC DNA (neutrophils were consistently negative).
Although we localized most of the BRAF  alleles in peripheral blood to the HLA-DR lineage
compartment of both LCH and ECD, some overspill was observed into the HLA-DR lineage  cells, owing
to this strategy. Although a proportion of this signal was contained in HLA-DR CD14  monocytes,
CD11c CD1c  myeloid progenitors that may generate macrophages are also found in this region. In
particular, ECD patients frequently have expanded myelopoiesis with an element of left shift that mobilizes
these cells into the peripheral compartment; thus, we cannot exclude a contribution of more primitive
myeloid precursors to the lesions of ECD. Notably, recent gene expression studies described enrichment for
myeloid progenitor signatures in ECD lesions.
There is significant interest in cell-free DNA as a marker of neoplasia, and this is also detectable in
histiocytosis.  In our hands, plasma cell-free BRAF  was approximately half-log lower in abundance
than cell-associated alleles. We considered the possibility that exogenous DNA might account for the
mutant alleles found in PBMCs, especially as the signal was localized to monocytes with phagocytic
activity. However, exposure of healthy control blood to BRAF-mutated genomic DNA did not result in a
cell-associated signal. Furthermore, the lack of mutated alleles in neutrophils, but the localization of
mutation to nonphagocytic CD34  progenitor cells, argues against phagocytic uptake of exogenous DNA as
a significant source of artifact.
Total RNA profiling reveals a strong DC-related and macrophage-related signature in LCH and ECD,
respectively.  However, there was no bias in the distribution of mutated alleles to suggest that the
phenotypic differences of LCH and ECD lesions are determined by the myeloid lineages harboring BRAF
mutation. This may not be surprising given the relatively high incidence of overlap cases now
documented.  Many alternatives may explain the variation between LCH and ECD, such as genetic
background, age-related myeloid hematopoietic bias,  additional somatic mutation,  or extrinsic
inflammatory signals arising independently in the local tissue environment. The difference in median age of
onset between LCH and ECD is consistent with an influence of age-related myeloid bias or clonal
hematopoiesis. From a pathological perspective, the occurrence of LCH and ECD together in a single
lesion suggests a cell-intrinsic mechanism.  However, in cases where an overlap syndrome occurs with
distinct and characteristic anatomical distributions of each disease, the tissue environment may direct either
LCH- or ECD-like pathology, through extrinsic signals. In keeping with previous reports of expanded
myelopoiesis in MS-LCH,  we observed an increase in blood myeloid cells and BM myeloid progenitors
in adult LCH and ECD.
The differentiation of myeloid cells in response to cytokine and notch-mediated signaling showed that >1
precursor has the potential to form cells with characteristic properties of LCH and ECD histiocytes (
Figure 6). The critical role of notch signaling in permitting LC development from monocytes was first
reported in response to DLL1.  Without this signal, CD14  classical monocytes only express low langerin
and are unable to form langerin CD1a  cells containing Birbeck granules in response to GM-CSF and
TGF-β. In contrast, CD1c  DCs spontaneously express langerin in vivo  and rapidly acquire LC-like
properties when exposed to GM-CSF and TGF-β.  In vitro differentiation experiments presented here
clearly show that 2 pathways may generate langerin  cells and that DLL4 provides a more potent signal
for monocytes than DLL1. Recent molecular studies have shown that DLL1 induces LC development in
monocytes by downregulating KLF and depressing RUNX3.  Elevated GM-CSF, M-CSF, and FLT3
ligand have been reported in the serum of patients with LCH, consistent with a pathological role of these
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cytokines.  Intrinsic notch signaling was previously suggested as a key mechanism promoting LCH
pathogenesis, through expression of Jagged 2 by lesional histiocytes.  Taken together, these observations
do not support a simple dichotomous model that LCH arises from the DC pathway and ECD from the
monocyte-macrophage pathway of myeloid cell development. Classical monocytes appear able to
contribute to histiocytes of both disorders, depending on the signals they receive. CD1c  DCs, on the other
hand, were unable to form foamy macrophages when exposed to strongly macrophage-promoting
conditions of M-CSF and lipid-containing human serum. Both classical and nonclassical monocytes rapidly
differentiated into typical foam cells under these conditions. CD16  nonclassical monocytes are likely to be
heterogeneous and have also been characterized as DC-like.  It is possible that a subpopulation formed
the macrophages observed in culture as the final density was lower than for equivalent numbers of CD14
monocytes. Given the high proportion of BRAF-mutated alleles in CD16  monocytes, they may contribute
to histiocytes in the lesions of ECD, although they are reported to be unable to form giant cells. The
occurrence of mutated alleles in monocytes also presents the possibility that macrophages in LCH lesions
arise from the neoplastic clone. Previous studies show that M-CSF, one of the factors used to differentiate
foam cells, is significantly increased in MS-LCH.
An important caveat of the in vitro differentiation experiment is that healthy control cells without BRAF
mutation were used. In the absence of a surface antigen that can distinguish mutated and unmutated
progeny, this analysis cannot be performed with enriched BRAF-mutated cells isolated from patients. The
presence of mutation may not matter because ERK activation is a consequence of many of the stimuli used
in vitro. However, it remains hypothetically possible that intrinsic BRAF activation has other unanticipated
effects.
The finding that BRAF-mutated PBMCs are detected at higher levels in MS-LCH has potential utility as an
indicator of clinical risk and response to therapy, as suggested in children.  Our conclusion in adults is
based on only 8 patients and should be expanded to a larger cohort ideally. The sensitivity of detection
using allele-specific PCR is critical as less sensitive techniques failed to find BRAF mutation in peripheral
blood or BM fractions previously. BRAF  was detected in PBMCs of a subset of ECD patients, and
it remains to be determined, using a large group, whether this segregates with disease risk in ECD.
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Figure 1.
Open in a separate window
Patients. Summary of adult patients included in the study. Asterisks indicate the number of patients with BRAF
detectable in PBMCs. The BRAF wild-type (WT) ECD group includes 1 patient with RAS mutation. NT, not tested.
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Figure 2.
Detection of BRAF alleles. (A) A standard curve constructed using DNA purified from a dilution series of
BRAF -positive melanoma cell line A375 into WT Epstein-Barr virus–transformed lymphoblastoid cell line. The
quantitative limit of detection was 0.1%; the absolute limit of detection was 0.01% (positive outside of quantitative range
[POQR]). (B) BRAF  allele frequency in bulk PBMCs in cases of lesion BRAF  + LCH, LCH/ECD, and ECD.
Contingency of positive PBMCs upon MS-LCH tested by Fisher’s exact test. (C) Correlation between mutated allele
burden in cell-free plasma and PBMC DNA in LCH, ECD, and HCL. (Di) Test of exogenous free DNA uptake by PBMCs.
BRAF-mutated DNA (derived from melanoma cell line A375) was spiked into whole blood for 24 hours at room
temperature. Plasma and PBMCs were isolated by density centrifugation. DNA was extracted from both fractions and
subjected to allele-specific PCR. (Dii) Test of exogenous free DNA uptake by sorted cells incubated at 37°C for 24 hours
in medium supplemented with 20% human serum from a patient with HCL. DNA from supernatants and cell pellets, as
indicated, was subjected to allele-specific PCR. mDC, myeloid dendritic cell.
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Figure 3.
Open in a separate window
Allele-specific PCR of BRAF in PBMCs. (A) The distribution of BRAF  in PBMCs sorted into quadrants as
shown according to expression of HLA-DR and lineage. Pie charts summarize the distribution of mutant alleles in HCL,
LCH, and ECD. The area of each quadrant in the pie is proportional to the total number of mutant alleles in that quadrant
(ie, the percentage positivity of the quadrant multiplied by the number of cells in the quadrant). All patients had active
disease at the time of sampling. Two children with LCH included for comparison are indicated. Asterisk indicates the
threshold of detection for a negative result where cell numbers were limiting. (B) The distribution BRAF  among
peripheral blood cells showing the percentage of mutated alleles detected. Gray shading indicates positive fractions.
Asterisk indicates child with MS-LCH shown for comparison. All patients had active disease at the time of sampling.
Italics indicate those who had received prior treatment. B, B cell; Mono, monocyte; Neuts, neutrophil; NK, natural killer;
NT, not tested owing to lack of or insufficient material; pDC, plasmacytoid dendritic cell; T, T cell.
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Figure 4.
Open in a separate window
Mononuclear profile and BRAF allele frequency in CD34 BM progenitors. (A) Relative proportions of progenitor
fractions among CD34  BM mononuclear cells compared with healthy controls (n = 21), expressed as percentage of total
live cells. Error bars depict 95% confidence intervals of healthy controls. Populations: B/NK, B/NK cell progenitors;
LMPP, lymphoid-primed multipotent progenitors; MEP, megakaryocyte–erythroid progenitor; MPP, multipotent
progenitor. (B) The distribution of BRAF  among CD34  BM progenitors. Gray shading indicates positive fractions.
BM aspirate was obtained in parallel with the peripheral blood shown previously. *Child; NRAS  Sanger sequencing.
NT, not tested owing to insufficient number of cells.
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Figure 5.
Open in a separate window
In vitro differentiation potential of monocytes and myeloid DCs. (A) Sorted CD14  monocytes, CD16  monocytes,
and CD1c  myeloid DCs from healthy controls cultured for 3 days in conditions as shown. Langerin CD1a  gates
depicted contain LCH-like cells with Birbeck granules. Notch ligands DLL1 And DLL4 were presented on transfected
mouse OP9 cells. Representative data of 5 independent experiments. (B) Sorted CD14  monocytes, CD16  monocytes,
and CD1c  myeloid DCs from healthy controls cultured for 7 days with M-CSF and 5% human serum (HS) to reveal
potential to differentiate into foamy macrophages. Representative phase contrast images of 5 independent experiments.
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Table 1.
Table summarizing BRAF  mutant allele frequency among blood monocytes and myeloid DCs
(data from Figure 3) and the potential of WT cells to form langerin  LCH-like cells or foamy
macrophages in vitro
CD14 CD16 CD1c
% BRAF
 Median 0.38 1.36 0.2
 Range 0-18 0-45 0-8
Langerin potential
 GM-CSF + TGF-β − − ++
 +DLL1 + − +++
 +DLL4 +++ − +++
Foamy mac potential +++ +++ −
Frequency of langerin  indicated as follows: −, <10%; +, 10%-25%; ++, 26%-35%; +++, >35%.
V600E
high
V600E
+
high
Hematopoietic origin of Langerhans cell histiocytosis and Erdhe... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524529/?repor...
16 of 17 3/4/18, 10:12 AM
Figure 6.
Open in a separate window
Potential precursor pathways in MS-LCH and ECD. Schema summarizing potential precursor pathways in MS-LCH
and ECD based on the distribution of BRAF  alleles in peripheral blood and the differentiation potentials of healthy
control cells in vitro. A minority of cells (filled) in the BM and blood contain BRAF mutation. The principal observation is
that <1% clonal hematopoiesis gives rise to <3% mutated blood precursors that appear to be strongly selected for in
peripheral tissue environments, resulting in lesional histiocyte mutation levels of up to 100%. Lesions potentially consist
of >1 precursor as indicated by blue for CD1c  DCs, red for classical monocytes, and brown for nonclassical monocytes.
The depiction of lesion composition is conjectural and not based on experimental observation. Furthermore, additional
contributions from other, more primitive myeloid progenitors cannot be excluded at present.
Articles from Blood are provided here courtesy of American Society of Hematology
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